In a report released today, Ami Fadia from Needham maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $300.00. The company’s shares closed today at $279.25.
Fadia covers the Healthcare sector, focusing on stocks such as Biogen, Avadel Pharmaceuticals, and Merus. According to TipRanks, Fadia has an average return of 1.3% and a 48.53% success rate on recommended stocks.
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $314.57, representing a 12.65% upside. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $325.00 price target.
See the top stocks recommended by analysts >>
BIIB market cap is currently $39.11B and has a P/E ratio of 13.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
Read More on BIIB:
- Biogen, Eisai May Have an Alzheimer’s Beater on Their Hands
- RBC says hotline sign of possible imminent approval for Biogen
- Needham health/pharmaceuticals analysts hold analyst/industry conference call
- Biogen promotes Singhal to EVP, Head of Development
- Biogen Names Priya Singhal as Executive Vice President, Head of Development
